MA32132B1 - Utilisation de ranolazine pour traiter la douleur - Google Patents
Utilisation de ranolazine pour traiter la douleurInfo
- Publication number
- MA32132B1 MA32132B1 MA33137A MA33137A MA32132B1 MA 32132 B1 MA32132 B1 MA 32132B1 MA 33137 A MA33137 A MA 33137A MA 33137 A MA33137 A MA 33137A MA 32132 B1 MA32132 B1 MA 32132B1
- Authority
- MA
- Morocco
- Prior art keywords
- ranolazine
- pain
- treatment
- patient
- visceral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des procédés pour traiter un patient souffrant d'une douleur neuropathique ou nociceptive qui peut être de nature mécanique, viscérale et/ou inflammatoire, comprenant l'administration d'une quantité thérapeutiquement efficace de ranolazine à un patient qui en a besoin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2669908P | 2008-02-06 | 2008-02-06 | |
US5743708P | 2008-05-30 | 2008-05-30 | |
PCT/US2009/033464 WO2009100380A1 (fr) | 2008-02-06 | 2009-02-06 | Utilisation de ranolazine pour traiter la douleur |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32132B1 true MA32132B1 (fr) | 2011-03-01 |
Family
ID=40548472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33137A MA32132B1 (fr) | 2008-02-06 | 2010-09-01 | Utilisation de ranolazine pour traiter la douleur |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090203707A1 (fr) |
EP (1) | EP2252294A1 (fr) |
KR (1) | KR20110013348A (fr) |
CN (1) | CN101977605A (fr) |
AU (1) | AU2009212254A1 (fr) |
BR (1) | BRPI0908428A2 (fr) |
CA (1) | CA2713521A1 (fr) |
CO (1) | CO6290663A2 (fr) |
EA (1) | EA201070914A1 (fr) |
EC (1) | ECSP10010446A (fr) |
IL (1) | IL207292A0 (fr) |
MA (1) | MA32132B1 (fr) |
WO (1) | WO2009100380A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2523873T3 (es) | 2002-05-21 | 2014-12-02 | Gilead Sciences, Inc. | Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes |
US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
US20100292217A1 (en) * | 2009-05-14 | 2010-11-18 | Gilead Palo Alto, Inc. | Ranolazine for the treatment of cns disorders |
LT2464645T (lt) | 2009-07-27 | 2017-10-25 | Gilead Sciences, Inc. | Kondensuoti heterocikliniai junginiai, kaip jonų kanalų moduliatoriai |
CN103096977B (zh) | 2010-07-02 | 2017-02-15 | 吉利德科学公司 | 作为离子通道调节剂的稠杂环化合物 |
MX361350B (es) | 2011-05-10 | 2018-12-04 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal de sodio. |
TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
NO3175985T3 (fr) | 2011-07-01 | 2018-04-28 | ||
EP3083608B1 (fr) | 2013-12-19 | 2018-07-18 | Gilead Sciences, Inc. | Composés hétérocycliques condensés en tant que modulateurs de canaux ioniques |
EP3423057A1 (fr) | 2016-03-04 | 2019-01-09 | Gilead Sciences, Inc. | Compositions et combinaisons d'inhibiteurs de l'autotaxine |
WO2018098491A1 (fr) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Composés et procédés d'utilisation desdits composés |
BR112019010880A2 (pt) | 2016-11-28 | 2019-10-01 | Praxis Prec Medicines Inc | compostos e seus métodos de uso |
US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11731966B2 (en) | 2017-04-04 | 2023-08-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
SG11202011879RA (en) | 2018-05-30 | 2020-12-30 | Praxis Prec Medicines Inc | Ion channel modulators |
US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
WO2021108625A1 (fr) | 2019-11-27 | 2021-06-03 | Praxis Precision Medicines, Inc. | Formulations de modulateurs de canaux ioniques, et procédés de préparation et d'utilisation de modulateurs de canaux ioniques |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657264A (en) * | 1985-11-01 | 1987-04-14 | Ingersoll-Rand Company | Fluid seal assembly with segmented sub-assembly |
ZA904842B (en) * | 1989-06-23 | 1992-02-26 | Syntex Pharma Ltd | Novel methods of treatment using ranolazine and related piperazine derivatives |
US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
EP1259230A2 (fr) * | 2000-02-18 | 2002-11-27 | Cv Therapeutics, Inc. | Inhibiteurs partiels de l'oxydation d'acides gras pour le traitement de l'insuffisance cardiaque globale |
US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
ES2523873T3 (es) * | 2002-05-21 | 2014-12-02 | Gilead Sciences, Inc. | Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes |
US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
US20060177502A1 (en) * | 2005-01-06 | 2006-08-10 | Srikonda Sastry | Sustained release pharmaceutical formulations |
EP1951262A4 (fr) * | 2005-11-21 | 2010-09-15 | Univ Alabama | Procedes utilisant des composes de petites molecules a des fins de neuroprotection |
AU2007278877A1 (en) * | 2006-07-27 | 2008-01-31 | Gilead Palo Alto, Inc. | ALDH-2 inhibitors in the treatment of addiction |
US20080248112A1 (en) * | 2007-02-13 | 2008-10-09 | Brent Blackburn | Use of ranolazine for the treatment of coronary microvascular diseases |
EP2117508A1 (fr) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Solutions intraveineuses comprenant de la ranolazine |
WO2008124532A1 (fr) * | 2007-04-05 | 2008-10-16 | Cv Therapeutics, Inc. | Dérivés de quinazolinone en tant qu'inhibiteurs de l'aldh-2 |
EP2139480A1 (fr) * | 2007-04-12 | 2010-01-06 | CV Therapeutics Inc. | Ranolazine utilisée pour améliorer la sécrétion d'insuline |
CA2704981A1 (fr) * | 2007-11-06 | 2009-05-14 | Cv Therapeutics, Inc. | Inhibiteurs aldh-2 dans le traitement de troubles psychiatriques |
-
2009
- 2009-02-06 WO PCT/US2009/033464 patent/WO2009100380A1/fr active Application Filing
- 2009-02-06 AU AU2009212254A patent/AU2009212254A1/en not_active Abandoned
- 2009-02-06 EA EA201070914A patent/EA201070914A1/ru unknown
- 2009-02-06 BR BRPI0908428A patent/BRPI0908428A2/pt not_active Application Discontinuation
- 2009-02-06 CN CN2009801040287A patent/CN101977605A/zh active Pending
- 2009-02-06 CA CA2713521A patent/CA2713521A1/fr not_active Abandoned
- 2009-02-06 EP EP09707821A patent/EP2252294A1/fr not_active Withdrawn
- 2009-02-06 US US12/367,403 patent/US20090203707A1/en not_active Abandoned
- 2009-02-06 KR KR1020107019622A patent/KR20110013348A/ko not_active Application Discontinuation
-
2010
- 2010-07-29 IL IL207292A patent/IL207292A0/en unknown
- 2010-08-13 CO CO10099978A patent/CO6290663A2/es not_active Application Discontinuation
- 2010-09-01 MA MA33137A patent/MA32132B1/fr unknown
- 2010-09-03 EC EC2010010446A patent/ECSP10010446A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2009212254A1 (en) | 2009-08-13 |
EP2252294A1 (fr) | 2010-11-24 |
CA2713521A1 (fr) | 2009-08-13 |
US20090203707A1 (en) | 2009-08-13 |
EA201070914A1 (ru) | 2011-04-29 |
ECSP10010446A (es) | 2010-10-30 |
WO2009100380A1 (fr) | 2009-08-13 |
IL207292A0 (en) | 2010-12-30 |
BRPI0908428A2 (pt) | 2015-12-08 |
KR20110013348A (ko) | 2011-02-09 |
CN101977605A (zh) | 2011-02-16 |
CO6290663A2 (es) | 2011-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32132B1 (fr) | Utilisation de ranolazine pour traiter la douleur | |
MA31822B1 (fr) | Compositions et methodes d'utilisation de peptides pro-ilot et leur analogues | |
MA38144A1 (fr) | Compositions et procédés pour le traitement de protéinopathies | |
MA31605B1 (fr) | Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation | |
MA30632B1 (fr) | Anticorps humanisé | |
UA112434C2 (uk) | Антигензв'язувальний білок, який специфічно зв'язується з всма | |
TW200733976A (en) | Method for the treatment of cognitive dysfunction | |
MX2022005782A (es) | Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos. | |
TN2010000068A1 (en) | Anticorps anti-cd37 | |
MX2009012950A (es) | ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS. | |
MA31606B1 (fr) | Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation | |
BRPI0813699A2 (pt) | Formulações de proteína de fusão glp-1-fc | |
SG164369A1 (en) | Human anti-b7rp1 neutralizing antibodies | |
MA31202B1 (fr) | Procede de traitement du cancer | |
MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
EA201001865A1 (ru) | Противовоспалительные агенты | |
WO2008043107A3 (fr) | Utilisation d'antagonistes des jonctions occlusives pour traiter les affections abdominales inflammatoires | |
MA33743B1 (fr) | Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur | |
MA32056B1 (fr) | Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene | |
WO2011026125A3 (fr) | Compositions pharmaceutiques à rétention gastrique permettant une libération immédiate et prolongée d'acétaminophène | |
MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
EP2567701A3 (fr) | Traitement de l'insuffisance cardiaque chez les animaux mammifères non humains par un antagoniste de l'aldostérone. | |
MA33571B1 (fr) | Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline | |
MA31941B1 (fr) | Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine | |
MA33839B1 (fr) | Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs |